NASDAQ : AYTU
Aytu BioPharma, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 1.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 20.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 20.97M |
| Enterprise Value | 12.77M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 10.87M |
| Shares Outstanding | 10.87M |
| Shares Change (YoY) | +96.17% |
| Shares Change (QoQ) | +83.83% |
| Owned by Insiders (%) | 5.14% |
| Owned by Institutions (%) | 14.31% |
| Float | 7.69M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.36 |
| Forward PS | 0.31 |
| PB Ratio | 0.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.45 |
| P/OCF Ratio | 6.39 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 3.93 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.13 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | 5.57 |
| Interest Coverage | -4.39 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -52.55% |
| Return on Assets (ROA) | -4.54% |
| Return on Invested Capital (ROIC) | -28.46% |
| Return on Capital Employed (ROCE) | -16.52% |
| Weighted Average Cost of Capital (WACC) | 6.64% |
| Revenue Per Employee | $757,500 |
| Profits Per Employee | -$187,526 |
| Employee Count | 76 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.27 |
Taxes
| Measure | Value |
|---|
| Income Tax | 21,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -11.47% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 2.32 |
| Relative Strength Index (RSI) | 42.03 |
| Average Volume (20 Days) | 24,993 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 328,872 |
| Short Previous Month | 345,229 |
| Short % of Shares Out | 3.03% |
| Short % of Float | 4.28% |
| Short Ratio (days to cover) | 6.80 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 57.57M |
| Gross Profit | 36.82M |
| Operating Income | -8.32M |
| Pretax Income | -14.23M |
| Net Income | -14.25M |
| EBITDA | -4.39M |
| EBIT | -8.32M |
| Loss Per Share | -$1.16 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 26.31M |
| Total Debt | 18.11M |
| Net Cash | 8.20M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 35.27M |
| Book Value Per Share | 3.29 |
| Working Capital | 7.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 3.28M |
| Capital Expenditures | -29,000 |
| Depreciation & Amortization | 3.93M |
| Net Borrowing | -4.85M |
| Free Cash Flow | 3.25M |
| FCF Per Share | $0.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | 63.95% |
| Operating Margin | -14.44% |
| Pretax Margin | -24.72% |
| Profit Margin | -24.76% |
| EBITDA Margin | -7.62% |
| EBIT Margin | -14.44% |
| FCF Margin | 5.65% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -96.17% |
| Shareholder Yield | -96.17% |
| Earnings Yield | -59.94% |
| FCF Yield | 15.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.67 |
| Price Target Difference | 401.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 26.39% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.06 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |